scholarly journals Electrochemical Microsensors: Phase‐Regulated Sensing Mechanism of MoS 2 Based Nanohybrids toward Point‐of‐Care Prostate Cancer Diagnosis (Small 18/2020)

Small ◽  
2020 ◽  
Vol 16 (18) ◽  
pp. 2070097
Author(s):  
Zi Ying ◽  
Lingyan Feng ◽  
Dongqing Ji ◽  
Yuan Zhang ◽  
Wei Chen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Point Of Care ◽  
Prostate Cancer Diagnosis ◽  
Sensing Mechanism

scholarly journals Phase‐Regulated Sensing Mechanism of MoS 2 Based Nanohybrids toward Point‐of‐Care Prostate Cancer Diagnosis

Small ◽  
2020 ◽  
Vol 16 (18) ◽  
pp. 2000307
Author(s):  
Zi Ying ◽  
Lingyan Feng ◽  
Dongqing Ji ◽  
Yuan Zhang ◽  
Wei Chen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Point Of Care ◽  
Prostate Cancer Diagnosis ◽  
Sensing Mechanism

466: Age is an Independent Predictor of Bone Metastasis at Prostate Cancer Diagnosis

2007 ◽  
Vol 177 (4S) ◽  
pp. 156-156
Author(s):  
Andrea Salonia ◽  
Pierre I. Karakiewicz ◽  
Andrea Gallina ◽  
Alberto Briganti ◽  
Tommaso C. Camerata ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Cancer Diagnosis ◽  
Independent Predictor ◽  
Prostate Cancer Diagnosis

Cigarette smoking is not associated with prostate cancer diagnosis and aggressiveness: a cross sectional Italian study

2018 ◽  
Vol 70 (6) ◽  
Author(s):  
Cosimo De Nunzio ◽  
Giorgia Tema ◽  
Riccardo Lombardo ◽  
Alberto Trucchi ◽  
Mariangela Bellangino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cigarette Smoking ◽  
Cancer Diagnosis ◽  
Cross Sectional ◽  
Italian Study ◽  
Prostate Cancer Diagnosis

Disparities in Prostate Cancer Diagnosis, Treatment, and Survival Among Men with Disabilities

2020 ◽  
Author(s):  
Dong Wook Shin ◽  
Jinsung Park ◽  
Kyoung Eun Yeob ◽  
Seok Jung Yoon ◽  
Soong-nang Jang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Prostate Cancer Diagnosis

Novel approaches to improve prostate cancer diagnosis and management in early-stage disease

2012 ◽  
Vol 109 ◽  
pp. 1-7 ◽  
Author(s):  
Michael Marberger ◽  
Jelle Barentsz ◽  
Mark Emberton ◽  
Jonas Hugosson ◽  
Stacy Loeb ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Early Stage ◽  
Early Stage Disease ◽  
Prostate Cancer Diagnosis ◽  
Diagnosis And Management ◽  
Stage Disease ◽  
Novel Approaches ◽  
Improve Prostate Cancer

scholarly journals Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jaegeun Lee ◽  
Seung Woo Yang ◽  
Long Jin ◽  
Chung Lyul Lee ◽  
Ji Yong Lee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Prostate Biopsy ◽  
Peripheral Zone ◽  
Transitional Zone ◽  
Gray Zone ◽  
Prostate Cancer Diagnosis ◽  
Psa Density ◽  
Diagnosis Group ◽  
Predictive Rate

Abstract Background Serum prostate-specific antigen (PSA) is widely used in screening tests for prostate cancer. As the low specificity of PSA results in unnecessary and invasive prostate biopsies, we evaluated the clinical significance of various PSAs and PSA density (PSAD) related to peripheral zones in patients with gray zone PSA level (4–10 ng/mL). Methods A total of 1300 patients underwent transrectal ultrasonography-guided prostate biopsy from 2014 to 2019. Among them, 545 patients in the gray zone were divided into the prostate cancer diagnosis group and the non-prostate cancer diagnosis group, and PSA, relative extra transitional zone PSA (RETzPSA), estimated post holmium laser enucleation of the prostate PSA (EPHPSA), PSAD, peripheral zone PSA density (PZPSAD) and extra-transitional zone density (ETzD) were compared and analyzed using receiver-operating characteristics (ROC) analysis after 1:1 matching using propensity score. Results Area under the ROC curve values of PSA, EPHPSA, RETzPSA, PSA density, ETzD, and PZPSAD were 0.553 (95% CI: 0.495–0.610), 0.611 (95% CI: 0.554–0.666), 0.673 (95% CI: 0.617–0.725), 0.745 (95% CI: 0.693–0.793), 0.731 (95% CI: 0.677–0.780) and 0.677 (95% CI: 0.611–0.719), respectively. PSAD had 67.11% sensitivity, 71.71% specificity, and 70.34% positive predictive rate at 0.18 ng/mL/cc. ETzD had 69.08% sensitivity, 64.47% specificity, and 66.04% positive predictive rate at 0.04 ng/mL/cc. When the cut-off value of PSAD was increased to 0.18 ng/mL/cc, the best results were obtained with an odds ratio of 5.171 (95% CI: 3.171–8.432), followed by ETzD with 4.054 (95% CI: 2.513–6.540). Conclusions These results suggested that volume-adjusted parameters (ETzD and PSAD) might be more sensitive and accurate than various PSA in gray zone patients who required prostate biopsy to reduce unnecessary biopsy.

Sign in / Sign up

Export Citation Format

Share Document